Study of SNA028 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called SNA028 for people with advanced colorectal cancer that has grown after standard treatments. It aims to see if the drug can help shrink tumors or slow the cancer's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer confirmed by biopsy or cytology, and it has worsened after standard therapy.
- You have at least one tumor that can be measured on a scan.
- Your overall health is good enough to carry out daily activities (ECOG score 0 or 1).
- Your doctor expects you to live at least 6 more months.
- You have not had certain prior treatments (like radioactive therapies or other experimental drugs) within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This study tests a new imaging agent that may help see certain cancers (colorectal, gastric, or pancreatic) more clearly on PET scans. It may help doctors better understand your tumor and guide treatment decisions.
This study tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.